De Novo Letermovir for Primary Cytomegalovirus Prophylaxis in Seropositive Kidney Transplant Recipients Improves Tolerance and Maintains Higher Mycophenolate Doses at 12 Months (KIDNEY WEEK 2025) - Oct 18, 2025 - Abstract #TH-PO0960; Pres time: Nov 6, 2025; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "Background Letermovir (LTV) is indicated for cytomegalovirus (CMV) prophylaxis in high-risk KT recipients (KTRs), providing an alternative to the standard-of-care valganciclovir (VGC) with static renal dosing, reduced toxicity and comparable efficacy. Conclusion De novo LTV in R+ KTRs appears to be safe and effective. This study suggests antiviral prophylaxis is more likely to be successfully completed with LTV and is associated with less myelosuppression, permitting higher mycophenolate doses at 12 months and avoiding corrective healthcare resource utilization."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Leukopenia • Transplantation
|
|
Hanna L Kleiboeker; Michael J Scolarici; Jillian Leigh Descourouez; Christopher Saddler; Didier A. Mandelbrot; David P. Al-Adra; Margaret R. Jorgenson
|